Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
ekincare has raised a total funding of $22M since 2015 till date
Investment demonstrates confidence in America’s commitment to science and innovation
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Subscribe To Our Newsletter & Stay Updated